Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.

Article Details

Citation

Copy to clipboard

Sanghani NS, Haase VH

Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.

Adv Chronic Kidney Dis. 2019 Jul;26(4):253-266. doi: 10.1053/j.ackd.2019.04.004.

PubMed ID

31477256 [ View in PubMed

]

Abstract

Prolyl hydroxylase domain oxygen sensors are dioxygenases that regulate the activity of hypoxia-inducible factor (HIF), which controls renal and hepatic erythropoietin production and coordinates erythropoiesis with iron metabolism. Small molecule inhibitors of prolyl hydroxylase domain dioxygenases (HIF-PHI [prolyl hydroxylase inhibitor]) stimulate the production of endogenous erythropoietin and improve iron metabolism resulting in efficacious anemia management in patients with CKD. Three oral HIF-PHIs-daprodustat, roxadustat, and vadadustat-have now advanced to global phase III clinical development culminating in the recent licensing of roxadustat for oral anemia therapy in China. Here, we survey current clinical experience with HIF-PHIs, discuss potential therapeutic advantages, and deliberate over safety concerns regarding long-term administration in patients with renal anemia.

DrugBank Data that Cites this Article

Drugs

Vadadustat

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Vadadustat	Egl nine homolog 1	Protein	Humans	Yes	Inhibitor	Details
Vadadustat	Egl nine homolog 2	Protein	Humans	Yes	Inhibitor	Details
Vadadustat	Egl nine homolog 3	Protein	Humans	Yes	Inhibitor	Details
Vadadustat	Endothelial PAS domain-containing protein 1	Protein	Humans	Unknown	Stabilization	Details
Vadadustat	Hypoxia-inducible factor 1-alpha	Protein	Humans	Unknown	Stabilization	Details